A third of childhood cancer patients may be infertile

Childhood cancer patients face an uncertain future regarding whether they have remained fertile, and a recent German study makes this abundantly clear.

According to findings published in Deutsches Arzteblatt International, as many as 30 percent of childhood cancer survivors are suspected of being rendered infertile because of their anti-cancer treatments.

Researchers collected data from 2,754 participants (1,476 of whom had been treated for a leukemia subtype, and the rest, for solid tumors). Of those, 210 agreed to undergo fertility testing, and infertility was suspected in thirty percent.

Several chemotherapy drugs, especially a select few known to treat hematologic cancers, are known to be high-risk for loss of fertility. The same is true for radiotherapy, when the radiation is not focused and affects the groin.

Source: Medical News Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap